Novartis Ag (NVS) Cash from Investing Activities (2009 - 2026)

Novartis Ag has disclosed Cash from Investing Activities across 18 years of filings, most recently posting -$3.1 billion for Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 38.43% year-over-year to -$3.1 billion; the TTM figure through Jun 2026 stood at -$17.8 billion (down 178.51% YoY), while the FY2025 annual figure was -$4.9 billion, up 35.09% from the prior year.
• Cash from Investing Activities came in at -$3.1 billion for Q2 2026 at Novartis Ag, up from -$11.7 billion in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $10.7 billion in Q1 2023 to a low of -$11.7 billion in Q1 2026.
• Average Cash from Investing Activities over 5 years is -$1.1 billion, with a median of -$1.2 billion recorded in 2022.
• The largest YoY upside for Cash from Investing Activities was 1092.99% in 2022 against a maximum downside of 11965.31% in 2022.
• Over 5 years, Cash from Investing Activities stood at -$1.3 billion in 2022, then grew by 22.52% to -$1.0 billion in 2023, then plunged by 301.76% to -$4.1 billion in 2024, then jumped by 48.76% to -$2.1 billion in 2025, then plunged by 47.58% to -$3.1 billion in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$3.1 billion in Q2 2026, -$11.7 billion in Q1 2026, and -$2.1 billion in Q4 2025.